One of the major challenges in cell implantation therapies is to promote integration of the microcirculation between the implanted cells and the host. We used adipose-derived stromal vascular fraction (SVF) cells to vascularize a human liver cell (HepG2) implant. We hypothesized that the SVF cells would form a functional microcirculation via vascular assembly and inosculation with the host vasculature. Initially, we assessed the extent and character of neovasculatures formed by freshly isolated and cultured SVF cells and found that freshly isolated cells have a higher vascularization potential. Generation of a 3D implant containing fresh SVF and HepG2 cells formed a tissue in which HepG2 cells were entwined with a network of microvessels. Implanted HepG2 cells sequestered labeled LDL delivered by systemic intravascular injection only in SVF-vascularized implants demonstrating that SVF cell-derived vasculatures can effectively integrate with host vessels and interface with parenchymal cells to form a functional tissue mimic.
T issue replacement is a potential strategy for regeneration of different organs affected in multiple conditions such as organ failure and congenital abnormalities. Cell transplantation offers an alternative to treat patients with organ failure, such as in liver diseases 1, 2 . However, minimal engraftment is achieved with this approach 1, 3, 4 . One of the major caveats in tissue replacement therapies is to promote effective vascularization of the transplanted tissue in order to prevent death and promote engraftment of transplanted cells. Several approaches have been utilized in an attempt to promote vascularization of implanted tissues such as the delivery of angiogenic growth factors to recruit host vessels or co-implantation of endothelial and angiogenic signaling cells with target tissue cells (reviewed in 5, 6 ). Although considerable progress has been achieved, significant obstacles such as short half-life of growth factors in the tissues resulting in regression of newly formed vasculatures 7, 8 and potential source of endothelial and angiogenic signaling cells for human transplants still need to be addressed.
Adipose-derived stromal vascular fraction (SVF) cells are an attractive cell population identified for transplantation studies since human adipose tissue is an easily accessible and dispensable tissue source that can provide large numbers of cells suitable for implantation with little donor morbidity and patient discomfort. In addition, SVF cell preparations have been shown to be safely and effectively transplanted to either an autologous or allogeneic host and can be manufactured in accordance with Good Manufacturing/Tissue Practice guidelines 9 . SVF cells are obtained from the enzymatic digestion of adipose tissue to single cells followed by discarding adipocytes. They are a mix of heterogeneous cell populations composed of endothelial cells, fibroblasts, perivascular cells, immune cells and undefined stem cell sub-populations [10] [11] [12] . The potential of SVF cells to promote vascularization and improve organ function when delivered to sites of ischemia has been demonstrated in animal models of peripheral ischemic disease [13] [14] [15] and myocardial infarction 16, 17 . Here, our goal was to harness the vascularization potential of SVF cells in vivo to generate an effective vascular interface between host and transplanted liver cells resulting in a functional tissue mimic. We show that (1) adipose-derived SVF cells have a potent intrinsic vascularizing potential, (2) culturing freshly isolated SVF cells retains this vascularization potential despite possible changes in cell populations, and (3) SVF cell-derived vasculatures form a functional interface between host and implanted parenchymal cells. parenchymal cells. The freshly isolated stromal vascular fraction (SVF) from adipose is rich in vascular and other relevant cells 18 capable of incorporating into vessels in vivo 14 . Similarly, cultured SVF cell populations also exhibit vascularizing potential 19, 20 , supporting the use of both fresh and cultured SVF cells (fSVF and cSVF, respectively) as cell sources in transplantation therapies. Based on these past findings, we hypothesized that adipose SVF cells alone are capable of forming de novo a new vasculature that would be amenable to use in vascularizing a tissue mimic. To test this hypothesis, we used SVF cell preparations from transgenic rats ubiquitously expressing GFP 21 to form implants. As predicted, both fSVF and cSVF cells in a simple 3D collagen matrix free of exogenous growth factors self-assembled to form a perfused vasculature (Fig. 1) . For both SVF cell preparations, complete vascular trees consisting of arterioles, capillaries and venules were observed and comprised entirely of GFP 1 cells, indicating an SVF origin (Fig. 1) . While both fSVF and cSVF generated perfused vasculatures, those formed by cSVF had lower vessel densities than fSVF-derived vasculatures (fSVF, 94.9 6 22; cSVF, 59.2 6 8 vessels/field of view) and total vessel perfusion was significantly less, (fSVF, 97.4 6 0.8; cSVF, 86.7 6 1.9) (Fig. 1) . Additionally, the average vessel diameter within the cSVF-formed vasculatures was significantly higher suggesting a lower proportion of smaller capillary-like diameters than in fSVF-formed vasculatures (fSVF, 11.7 6 1.5; cSVF, 14.6 6 2.3) (Fig. 1) .
Adipose stromal vascular fraction cells contribute to angiogenesis. Another critical issue with functionalizing an implanted tissue mimic is efficient integration between the mimic-host vasculatures. Using an experimental model of neovascularization involving the implantation of angiogenic microvessels 22, 23 , we next investigated the ability of SVF cells to incorporate into an angiogenic vascular bed, an activity essential to vascular integration. As with de novo vessel assembly, both fresh and cultured SVF cells participated in the formation of new vessel elements during active angiogenesis (Fig. 2) . During the early phases of neovascularization, which is dominated by angiogenesis and immature network formation, SVF cells were intimately associated with the nascent, endothelial cellderived neovessels throughout the developing neovasculature. In the later implants, the mature vasculatures that formed were comprised of GFP 1 (i.e. SVF-derived) and GFP-negative (i.e. non-SVF-derived) cells (Fig. 2) . Moreover, many of the non-SVF-derived vessels were populated with SVF cells or were chimeras of non-SVF-derived and SVF-derived vessel segments (Fig. 2) . In mature angiogenic implants containing fSVF, GFP 1 cells were observed in endothelial and perivascular positions of all vessel types. In contrast, cSVF cells were found predominately in perivascular positions and rarely in the endothelial position (Fig. 2) . In addition, the extent of cSVF cell incorporation into the formed vasculature was approximately half that of fSVF cells (fSVF, 24.6 6 10.4%; cSVF, 13 6 6.6%) (Fig. 2) .
Cultured SVF cells have fewer CD31 and cKit positive cells than fresh SVF cells. These differences in incorporation potential and vascular position suggest that submitting SVF cells to culture promotes either a selection of a perivascular phenotype or changes in the population potential. To investigate the different cell populations present in fresh and cultured SVF, we assessed the expression of different cell type markers by flow cytometry (Fig. 3) . Consistent with the vascularizing potential and predicted from a related study 14 , cSVF cell population contains less than half the number of CD31 1 cells (presumably endothelial cells) than fSVF cells (Fig. 3) . Similarly, the proportion of c-Kit 1 progenitor cells was greatly reduced in cSVF cells as compared to fSVF cells. However, the proportions of cells expressing markers for monocyte/macrophages (CD14), perivascular cells (PDGFR-b) and multipotent cells (CXCR4, c-Met) was not different (Fig. 3) . The similar presence of PDGFR-b 1 cells in both SVF preparations might explain the shared potential for establishing mural/perivascular coverage of the new vessel elements.
Human freshly isolated adipose SVF cells vascularize implanted parenchymal cells. Having demonstrated the vascularizing potential of SVF cells using a transgenic lineage marker, we next determined the vascularizing potential of clinically relevant human SVF cells. To do this, we repeated the above de novo assembly experiments using www.nature.com/scientificreports freshly isolated SVF cells derived from discarded lipo-aspirates with the exception that the SVF cells in collagen constructs were implanted for 6 weeks instead of 4 weeks. As with the rat SVF cells, the human SVF cells were also able to self-assemble into a vascular network, although the human SVF-derived network may still be undergoing neovascular remodeling 24 at this time (Fig. 4) . To determine if the human SVF cells retained this ability to assemble a vasculature de novo in the presence of parenchyma cells, we implanted constructs containing human SVF with HepG2 cells, an hepatocyte-like cell line 25 , grown on Cytodex-3 beads to maintain the hepatocyte-like phenotype in the 3-D environment 26 . As before, the human SVF cells assembled a vascular network in these implants (Fig. 4) . Interestingly, human SVF-derived vessel networks formed around and in close approximation to the HepG2 clusters (Fig. 4) .
Freshly isolated adipose SVF cells functionally interface with implanted parenchymal cells. Because of the close association between SVF cell-derived vessels and HepG2 clusters, we next determined if this vascularized cell system was functional. To do this, we took advantage of the fact that HepG2 cells express the LDL receptor and take up LDL similar to mature hepatocytes 27 by examining LDL uptake in the vascularized implants. As expected, HepG2 cell implants vascularized with fresh SVF cells took up DiIlabeled LDL (DiI-LDL) injected intravenously into the host mouse ( Fig. 5 ). Approximately 83% of the HepG2 clusters were associated with a vascular network or DiI-LDL uptake, while approximately 67% of the HepG2 clusters were associated with both. Further analysis indicates a strong correlation (r 5 0.909) between the presence of vessels and DiI-LDL uptake by HepG2 cell clusters (Fig. 5) . Indeed, HepG2 clusters not associated with a vasculature did not co-localize with DiI-LDL despite DiI-LDL uptake by host liver (Fig. 5 ).
Discussion
With a relatively simple strategy, we show for the first time that functional, vascularized tissue mimics can be generated by combining parenchymal and adipose-derived SVF cells. In this case, the tissue mimic was a model liver module using a human model hepatocyte cell line (HepG2) as the parenchyma. Central to this strategy is the ability of adipose-derived SVF cells (either freshly isolated or cultured) to spontaneously form de novo a mature microvasculature. Importantly, the uptake of LDL by the HepG2 cells demonstrates that this formed microvasculature serves as a functional vascular interface between the host circulation and the parenchymal cells. The vascular-parenchyma integration observed in the SVF-based implant, intrinsic to native tissues, highlights the therapeutic potential of this implant design/strategy. While we demonstrated proof-of-principle using a liver tissue mimic, we envision this use of adipose SVF cells as an enabling solution with broad applicability. Related to this and due to the inherent vascularization ability of isolated adipose SVF cells, we envision a point-of-care strategy whereby freshly harvested SVF cells from readily acquired lipoaspirates can be used in an autologous fashion. Conversely, given that cultured SVF cells retain the ability to form de novo blood-perfused vasculatures, a more therapeutically convenient ''off-the-shelf '' approach could be employed by using banked, pooled adipose SVF cells expanded by culture (albeit low passage number). The low immunogenicity of adipose-derived cells 16, 28 makes the allogeneic approach feasible. This immune-privileged aspect of adipose SVF cells may even facilitate the use of allogeneic parenchymal cells in the implant design should an autologous solution not be available 29, 30 . Finally, multiple Phase I clinical trials using different adipose-derived SVF preparations as a source for therapeutic mesenchymal cells indicate that these cells are very safe 31 . Previous attempts towards the development of vascularized liver grafts for transplantation consisted of incorporating vascular endothelial growth factor into scaffolds to enhance vascularization of transplanted hepatocytes 32 . However, the authors did not investigate vessel perfusion or function of implanted hepatocytes. Here we demonstrate that when combined with HepG2 parenchymal cells, SVF cell-derived vasculatures envelop these cells, forming a functional interface. Indeed, we demonstrate the effective integration of transplanted liver tissue mimics six weeks post-implantation through the metabolic interaction between SVF formed vessels and parenchyma cells, as illustrated by the uptake of fluorescently labeled LDL by HepG2 cells. This proof-of-principle system suggests that other therapeutic cells could be combined with SVF to form modular tissue mimics for delivery or removal of circulating biomolecules.
The simple liver tissue mimic was developed as a modular system designed to perform a specific function (LDL uptake in this case). Similarly, tissue mimic modules with different functional purposes could be assembled by incorporating different parenchymal cells along with the vascularizing adipose SVF cells. In this way, via our modular approach, more complex organoids capable of performing multiple, potentially integrated, physiological functions could be generated by combining these different multiple tissue mimics. This modular strategy is also scalable by simply implanting more or less of the modules to meet therapeutic need. Additionally, select modules (or all) could be removed should there be an unexpected, deleterious outcome to the implantation (e.g. infection). Depending on the configuration, these mimics, such as the liver mimic presented here, could prove useful not only as an implantable functional replacement (e.g. LDL clearance) for regenerative medicine, but also as a human model tissue system for triaging/developing drug candidates targeting specific parenchyma types, evaluating drug metabolism (as with the hepatocyte-like module), and other translational and mechanistic investigations.
While the inherent vascularization capability of adipose SVF cells is maintained in early passage culture, the capacity of these cells to incorporate into vascular sites of neovascularization (i.e. angiogenic neovessels) is altered, suggesting that culturing has an effect on the SVF cells. This is demonstrated not only by the significant decrease in SVF incorporation into formed neovessels but also by the position of the incorporated cells (endothelial and perivascular for fresh SVF; mostly perivascular for cultured SVF). Flow cytometry of select markers revealed a significant decrease in the percentage of CD31 1 and cKit 1 cells after culture, suggesting a reduction in the proportion of endothelial cell phenotypes [33] [34] [35] . This reduction corresponds to a lower density (i.e. number) of vessels formed de novo by the cultured SVF cells and is consistent with the idea that the endothelial cells present in an adipose SVF cell isolate are required for vascular assembly 14 . Interestingly, the proportion of cells with perivascular phenotype (PDGFR-b 1 cells) 36, 37 did not change with culture. Again, this is consistent with the observation that cultured SVF cells preferentially incorporated into the mural position in angiogenic neovessels.
It's important to note that plating and culture conditions we employed differ from those used by others selecting for adiposederived stem cells (ADSC) 20, 38 . While there are cells expressing mesenchymal stem cell-like markers in our early-passage, cultured SVF cells, we clearly have mixed cell phenotypes present that are not typically observed in the other reported ADSC phenotypes. These mixed phenotypes observed in our cultured SVF cells may explain why the cultured SVF cells are able to generate de novo a vasculature (as all necessary cell types appear to be present), albeit to a lesser extent than with the freshly isolated SVF cells. Whether or not extended culturing of the SVF cells (beyond P0 or P1) alters further cell phenotypes and, consequently, the vascularizing ability remains to be determined.
One of the most intriguing aspects of the current study is the ability of SVF cells, either fresh or cultured, to go from a single-cell suspension to a self-assembled functionally mature vasculature. At present it is unknown how this heterogeneous cell mix works together to reassemble back into a vasculature or which specific cell types are necessary. As shown by Koh, et al 14 , and indicated here, endothelial cells play an essential role in this process. However, endothelial cells alone are insufficient to form a mature vasculature either in vitro 39 or in vivo 40 . Clearly non-endothelial support cells are required to achieve vessel stabilization and maturation 39, 41 . Within the SVF are these support cells, such as perivascular cells and/or mesenchymal stem cells. But, also other stromal cells present in the isolate, such as fibroblasts and macrophages, may be important 12, 42 . Although it is possible that vascular beds from all tissues 22 , when isolated and disassembled, would show the same self-assembly capacity as demonstrated here by adipose-derived SVF cells, the adipose vasculature has been proposed to be evolutionarily less mature than other more quiescent vascular beds and thus more plastic 43 . Perhaps this plasticity is important to allow tissue, and thus vascular, remodeling in response to the energy storage requirements of adipose tissue 43 . Besides its relative abundance and accessibility compared to other adult cell sources, these results highlight adipose-derived SVF clinical utility for vascularization under a variety of relevant conditions.
In conclusion, we demonstrate for the first time that adipose SVF cell-derived vasculatures from rodent and human sources can effectively integrate with host vessels and interface with parenchymal cells (model hepatocyte cells in this case) to form a functional, implanted tissue mimic module and proof-of-principle therapeutic potential. This enabling technology can also be expanded to generate a variety of tissue mimics and cellular modules, by simply changing the parenchymal cell type (e.g. cardiomyocytes, b-cells, or engineered therapeutic cells). The LDL uptake observation suggests that the adipose-derived vasculatures in these implant modules can acquire functional specificity, an important aspect for therapeutic efficacy and mimic function. This approach whereby abundant therapeutic cells are utilized without selection or further manipulation, beyond the initial isolation process, creates new avenues towards tissue mimic and therapeutic applications including the ability to incorporate disease-and/or patient-specific dynamics. Flow cytometry analysis. cSVF were dissociated with non-enzymatic Cell Dissociation Buffer (Sigma) after reaching confluence (P0) and fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were blocked with PBS containing 5% fetal bovine serum (FBS) for 30 minutes on ice and incubated with the following antibodies in blocking buffer on ice for 1 hour: anti-CD14 (15100), anti-CD31-APC (15500)(BD Biosciences); anti-cKit (15100, Abcam); anti-CXCR4 (15100, Ebiosciences); anti-c-Met (15100), anti-PDGFR-b (15100, Santa Cruz Biotechnology) overnight at 4uC. Secondary antibodies used were anti-mouse-Alexa Fluor 488 (15400)(Jackson ImmunoResearch) and anti-rabbit-Cy6 (15500)(Jackson ImmunoResearch) for 30 min at 4uC.
Methods
Microvessel isolation. Fat-derived microvessels (FMF) were isolated from rat epididymal fat by limited collagenase digestion and selective screening as previously described 44, 45 . The collagenase used (type I; Worthington Biochemical Company, Freehold, NJ, USA) was lot tested to yield high numbers of fragments with intact morphologies. These vessel fragments have the potential to form a microcirculation composed of different vessel types 4 weeks post implantation in vivo in 3-dimensional collagen gels 23 .
HepG2 cell culture. HepG2 cells were cultured in T-75 tissue culture flasks in HepG2 growth media consisting of Dulbecco's Modified Eagle's Media high glucose, 10% fetal bovine serum, 13 penicillin/streptomycin, and 13 L-glutamine (Invitrogen Camarillo, CA, USA). Media was changed every other day and cells were grown to confluence at which time they were prepared for Cytodex-3 culture as described below. Plasmids and Cell Transduction HepG2 were transduced with retrovirus to constitutively express GFP (pBMN-I-GFP) or Ds-Red as previously described 46 .
Cytodex-3 cell culture. 47, 48 . PBS solution was removed and washed out with freshly prepared 70% ethanol for total of four washes. The last 70% ethanol wash was carried overnight. The following day, ethanol was removed and 10 mL of HepG2 growth media was added for a total of four washes. The last wash was removed and HepG2 cells were passaged into a resuspension of 1 3 10 6 cells/mL. 6 3 10 6 cells were added to 4 mL of HepG2 media containing Cytodex-3 beads and gently mixed. The bead-cell mixture was added to a 100 mm petri dish (BD Falcon) and incubated for three days at 37uC and 5% CO 2 for optimal microcarrier coverage.
Preparation of 3-dimensional constructs and in vivo implantation. To form the 3D constructs, fresh or cultured SVF (10 6 cells/mL) were suspended into 3 mg/mL of collagen type I (BD Biosciences, San Jose, CA, USA) and 0.2 mL of the suspension was seeded into wells of 48-well culture plates. Constructs were implanted subcutaneously on the flanks of Rag1 mice as previously described 22 . To assess the potential of fresh and cultured SVF to participate in the neovascularization process, fresh or cultured SVF from GFP rats (10 6 cells/mL) were seeded into collagen gels concomitantly with isolated FMFs (20,000/mL). FMF/SVF/collagen suspensions were pipetted into wells of a 48-well culture plate (0.2 mL/well) to form a 3D construct that were either cultured in DMEM 1 10% FBS or implanted subcutaneously on the flanks of Rag1 mice as previously 24 . Alternatively, SVF were seeded in the presence of HepG2 cells before implantation.
Implant analysis. Microvascular constructs were harvested at either 4 or 6 weeks after implantation and fixed in 4% paraformaldehyde for 20 minutes. Samples were permeabilized with 0.5% Triton X-100 and rinsed with PBS. After blocking for two hours with 10% goat serum (Sigma), samples were incubated overnight with fluorescent or biotin conjugated lectins. Following three 15 minute washes in divalent cation free (DCF)-PBS, samples were imaged en bloc with an Olympus MPE FV1000 Confocal Microscope and analyzed with Amira 5.2 (Visage Imaging, Inc., San Diego, CA, USA). SVF cells were identified by either constitutive expression of GFP (when obtained from animals that ubiquitously and constitutively express GFP) or labeling with TRITC/Fluorescence conjugated or Cy5-streptavidin GSI (rodent SVF) or UEAI (human SVF) lectin (Vector labs, Burlingame, CA, USA). To evaluate vessel perfusion in the implanted constructs, host mice were perfused intravenously with the blood tracer dextran-TRITC 2,000,000 MW for 15 minutes before the constructs were harvested. Confocal microscopy images of implants (from 3-12 image stacks per each of 5 implants) with HepG2-GFP 1 clusters were identified and examined for presence of GS1-Cy5 1 vasculature, DiI-LDL, or both. Those images without HepG2-GFP 1 clusters were not included. Significant differences between HepG2-GFP 1 clusters with both GS1-Cy5 1 vessels and DiI-LDL and those with either one or the other or none were determined using a two-tailed t-test between the sample pairs of interest. To determine if DiI-LDL uptake is correlated with the presence of GS1-Cy5 1 vasculature, HepG2-GFP 1 clusters positive for DiI-LDL were plotted against those clusters positive for GS1-Cy5 vasculature. The Pearson correlation coefficient was then calculated for statistical correlation between the two variables. Significant differences in measured parameters (Figs. 1-3 ) between fresh and cultured SVF cells (n 5 3/condition) was determined by a Student's t-test with a normality check.
